![](/img/cover-not-exists.png)
PCV90 THE COST-EFFECTIVENESS OF ROSUVASTATIN VERSUS SIMVASTATIN FOR THE PREVENTION OF CARDIOVASCULAR MORBIDITY AND MORTALITY IN PATIENTS WITH HIGH BASELINE RISK—A SWEDISH ECONOMIC EVALUATION BASED UPON THE JUPITER TRIAL
AG Olsson, MM Jensen, SK Gandhi, L Smolen, T PaulssonVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)72432-9
File:
PDF, 77 KB
english, 2010